Written by Tracey Walker

***excerpt***

Healthcare executives should view American Patients First—The Trump Administration Blueprint to lower dug prices and reduce out-of-pocket costs—as well as the subsequent flurry of drug pricing administrative actions across Medicare Part B and Part D, as a “clear sign that the Administration is serious about pursuing significant policy changes across payers,” according to Lindsay Bealor Greenleaf, director at healthcare advisory firm ADVI Health.

***end excerpt***

***

[/el-text]

View full article here